0
Articles   |    
Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study
Priya Wickramaratne, Ph.D.; Marc J. Gameroff, Ph.D.; Daniel J. Pilowsky, M.D., M.P.H.; Carroll W. Hughes, Ph.D.; Judy Garber, Ph.D.; Erin Malloy, M.D.; Cheryl King, Ph.D.; Gabrielle Cerda, M.D.; A. Bela Sood, M.D.; Jonathan E. Alpert, M.D., Ph.D.; Madhukar H. Trivedi, M.D.; Maurizio Fava, M.D.; A. John Rush, M.D.; Stephen Wisniewski, Ph.D.; Myrna M. Weissman, Ph.D.
From Columbia University and the New York State Psychiatric Institute; the University of Texas Southwestern Medical Center; Duke University-National University of Singapore; Vanderbilt University; the University of North Carolina; the University of Michigan; the University of California at San Diego; Virginia Commonwealth University; Harvard University; and the University of Pittsburgh.
Am J Psychiatry 2011;168:593-602. 10.1176/appi.ajp.2010.10010032
View Author and Article Information

Received Jan. 8, 2010; revision received Nov. 18, 2010; accepted Dec. 13, 2010.

Dr. Pilowsky reports financial support from NIMH, NIDA, and CDC. Dr. Alpert receives research support from Aspect Medical Systems, Eli Lilly, PamLab, and Pfizer, and he receives honoraria from Reed Medical Education and Belvoir Publishing. Dr. Trivedi has received research support from the Agency for Healthcare Research and Quality (AHRQ), Corcept Therapeutics, Cyberonics, Merck, National Alliance for Research in Schizophrenia and Depression, NIMH, National Institute on Drug Abuse, Novartis, Pharmacia & Upjohn, Predix EPIX Pharmaceuticals, Solvay Pharmaceuticals, and Targacept. He has received consulting and speaker fees from Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), AstraZeneca, Bristol-Myers Squibb, Cephalon, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Eli Lilly, Meade Johnson, Medtronic, Neuronetics, Otsuka Pharmaceuticals, Parke-Davis Pharmaceuticals, Pfizer, Sepracor, SHIRE Development, VantagePoint, and Wyeth-Ayerst Laboratories. Dr. Fava has received research support, advisory or consulting fees, and speaking or publishing fees from AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Novartis AG, Organon Pharmaceuticals, and Pfizer. He has received research support and advisory or consulting fees from Abbott Laboratories, Alkermes, Aspect Medical Systems, BrainCells, CeNeRx BioPharma, Clinical Trials Solutions, Euthymics Bioscience, i3 Innovus/Ingenix, Johnson & Johnson PRD, Lorex Pharmaceuticals, PamLab, Pharmavite, Roche, RCT Logic, Sanofi-Aventis US, Solvay Pharmaceuticals, and Synthelabo. Dr. Fava has also received research support from BioResearch, Clintara, Covidien, EnVivo Pharmaceuticals, Ganeden Biotech, Icon Clinical Research, Lichtwer Pharma GmbH, NARSAD, NCCAM, NIDA, NIMH, Photothera, Shire, and Wyeth-Ayerst Laboratories. He has also received advisory or consulting fees from Affectis Pharmaceuticals AG, Amarin Pharma, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management, BioMarin Pharmaceuticals, Biovail Corporation, CNS Response, Compellis Pharmaceuticals, Cypress Pharmaceutical, DiagnoSearch Life Sciences, Dinippon Sumitomo Pharma, Dov Pharmaceuticals, Edgemont Pharmaceuticals, Eisai Inc., ePharmaSolutions, EPIX Pharmaceuticals, Fabre-Kramer Pharmaceuticals, GenOmind, Grunenthal GmbH, Janssen Pharmaceutica, Jazz Pharmaceuticals, Knoll Pharmaceuticals, Labopharm, Lundbeck, MedAvante, Merck, MSI Methylation Sciences, Naurex, Neuronetics, NextWave Pharmaceuticals, Nutrition 21, Orexigen Therapeutics, Otsuka Pharmaceuticals, Pharma-Star, PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa Pharmaceuticals, Puretech Ventures, PsychoGenics, Psylin Neurosciences, Rexahn Pharmaceuticals, Ridge Diagnostics, Sepracor, Servier Laboratories, Schering-Plough Corporation, Somaxon Pharmaceuticals, Somerset Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company Limited, Tal Medical, Tetragenex Pharmaceuticals, TransForm Pharmaceuticals, Transcept Pharmaceuticals, and Vanda Pharmaceuticals. Dr. Fava has also received speaking or publishing fees from Adamed, Advanced Meeting Partners, American Psychiatric Association, American Society of Clinical Psychopharmacology, Belvoir Media Group, Boehringer Ingelheim GmbH, CME Institute/Physicians Postgraduate Press, Imedex, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed Elsevier, PharmaStar, United BioSource, and Wyeth-Ayerst Laboratories. Dr. Fava has equity holdings in Compellis and receives royalty, patent, or other income from a patent for SPCD and patent application for a combination of azapirones and bupropion in major depressive disorder, copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER. He has a patent for research and licensing of SPCD with RCT Logic; Lippincott, Williams & Wilkins. Dr. Rush has received consultant fees from Advanced Neuromodulation Systems, AstraZeneca, Best Practice Project Management, Brain Resource, Bristol-Myers Squibb/Otsuka, Cyberonics, Forest Pharmaceuticals, Gerson Lehrman Group, GlaxoSmithKline, Jazz Pharmaceuticals, Magellan Health Services, Merck & Company, Neuronetics, Novartis Pharmaceuticals, Ono Pharmaceuticals, Organon, Otsuka Pharmaceuticals, Pamlab, Pfizer, The University of Michigan, Transcept Pharmaceuticals, Urban Institute and Wyeth Ayerst; speaking fees from Cyberonics, Forest Laboratories, GlaxoSmithKline, and Otsuka; royalties from Guilford Publications, Healthcare Technology Systems, and The University of Texas Southwestern Medical Center; and research support from NIMH and the Stanley Medical Research Institute. He has owned shares of stock in Pfizer. Dr. Wisniewski has received consultant fees from Cyberonics, ImaRx Therapeutics, Bristol-Myers Squibb Company, Organon, Case-Western University, Singapore Clinical Research Institute, Dey Pharmaceuticals, Venebio, and Dey. The remaining authors report no financial relationships with commercial interests.

Supported by NIMH grant R01MH063852 (Dr. Weissman, principal investigator) and by an NIMH contract (N01 MH90003) (Dr. Rush, principal investigator). Dr. Garber was supported in part by an Independent Scientist Award K02 MH66249 from NIMH.

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Address correspondence and reprint requests to Dr. Weissman, Columbia University and New York State Psychiatric Institute, Unit 24, 1051 Riverside Dr., New York, NY 10032; mmw3@columbia.edu (e-mail).

Copyright © American Psychiatric Association

Abstract

Objective:  Maternal major depressive disorder is an established risk factor for child psychopathology. The authors previously reported that 1 year after initiation of treatment for maternal depression, children of mothers whose depression remitted had significantly improved functioning and psychiatric symptoms. This study extends these findings by examining changes in psychiatric symptoms, behavioral problems, and functioning among children of depressed mothers during the first year after the mothers' remission from depression.

Method:  Children were assessed at baseline and at 3-month intervals with the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version, the Child Behavior Checklist, and the Children's Global Assessment Scale for 1 year after their mothers' remission or for 2 years if the mothers did not remit. The authors compared children of early remitters (0—3 months; N=36), late remitters (3—12 months; N=28), and nonremitters (N=16).

Results:  During the postremission year, children of early-remitting mothers showed significant improvement on all outcomes. Externalizing behavioral problems decreased in children of early- and late-remitting mothers but increased in children of nonremitting mothers. Psychiatric symptoms decreased significantly only in children of mothers who remitted, and functioning improved only in children of early-remitting mothers.

Conclusions:  Remission of mothers' depression, regardless of its timing, appears to be related to decreases in problem behaviors and symptoms in their children over the year after remission. The favorable effect of mothers' remission on children's functioning was observed only in children of early-remitting mothers.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-IV-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 1. Participant Flow in the STAR*D-Child Studyaa Remission was defined as Hamilton Depression Rating Scale (HAM-D) score ≤7. Relapse was defined as HAM-D score ≥14 following remission.b Number of mothers with follow-up data. Twenty of the 127 were early or late remitters but were excluded from the analysis because they subsequently relapsed.c Excluded are three late remitters: two because of missing child or mother data after the remission date and one because remission occurred late during the second year of treatment.d Excluded are 24 nonremitters because child and/or mother data were unavailable after the first 12 months of treatment.

FIGURE 2. Analytic Design of the STAR*D-Child Study of Children's Outcomes in Relation to Illness Course of Mothers Treated for Depressionaa For each of the three groups, the horizontal timeline depicts the potential length of time (in months) spent in the study, zero-centered on the remission date (for remitters) or on the date 12 months after treatment initiation (for nonremitters). For remitters, the dotted portions of the lines signify time ranges in relation to the remission point during which treatment was initiated. The shaded area depicts the five potential assessments per participant that are analyzed in this study (at times 0, +3, +6, +9, and +12). For remitters, this covers the 12-month period following remission, and for nonremitters, it covers the 12-month period following the first 12 months of participation in the study, given the absence of remission during those first 12 months.
Anchor for Jump
TABLE 1.

Baseline Demographic and Clinical Characteristics of Depressed Mothers and Their Children by Maternal Depression Remission Status (N=80)

Table Footer Note

a Fisher's exact test (calculated because >20% of the cells had expected counts <5).

Table Footer Note

b K-SADS-PL=Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version.

Table Footer Note

c Kruskal-Wallis chi-square statistic.

Anchor for Jump
TABLE 2.

Current Symptoms and Functioning Over 1 Year for Children of Depressed Mothers, by Maternal Remission Status (N=80)a

Table Footer Note

a In all regressions, we controlled for household income; mother's marital status (except for the outcome of mother's report of children's symptoms, which was not significantly associated with marital status); mother's baseline Hamilton Depression Rating Scale score, generalized anxiety disorder at baseline (1=yes, 0=no), and substance-related disorder at baseline (1=yes, 0=no); and child's age, gender, baseline score on the particular measure being analyzed, and whether he or she received mental health treatment at any time during the study (1=yes, 0=no).

Table Footer Note

b Symptoms from the Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime Version.

Table Footer Note

c There was a marginally significant difference in time trend of Child Behavior Checklist total scores among the three groups (F=2.90, df=2, 221, p=0.057). Post hoc tests revealed that the time trend for children of nonremitters was different from the time trends for children of early (t=2.83, df=151, p=0.005) and late (t=3.14, df=113, p=0.002) remitters. The time trends for children of early and late remitters were not significantly different from each other.

Table Footer Note

e There was a significant difference in time trend of Child Behavior Checklist externalizing scores among the three groups (F=3.59, df=2, 220, p=0.03). Post hoc tests revealed that the time trend for children of nonremitters was different from the time trends for children of early (t=1.92, df=152, p=0.057) and late (t=3.01, df=114, p=0.003) remitters. The time trends for children of early and late remitters were not significantly different from each other.

Table Footer Note

* p<0.05; **p<0.01.

+
Weissman  MM;  Gammon  GD;  John  K;  Merikangas  KR;  Warner  V;  Prusoff  BA;  Sholomskas  D:  Children of depressed parents: increased psychopathology and early onset of major depression.  Arch Gen Psychiatry   1987; 44:847—853
[PubMed]
[CrossRef]
 
Weissman  MM;  Wickramaratne  P;  Nomura  Y;  Warner  V;  Pilowsky  D;  Verdeli  H:  Offspring of depressed parents: 20 years later.  Am J Psychiatry   2006; 163:1001—1008
[CrossRef] | [PubMed]
 
Weissman  MM;  Wickramaratne  P;  Nomura  Y;  Warner  V;  Verdeli  H;  Pilowsky  DJ;  Grillon  C;  Bruder  G:  Families at high and low risk for depression: a 3-generation study.  Arch Gen Psychiatry   2005; 62:29—36
[CrossRef] | [PubMed]
 
Klein  DN;  Lewinsohn  PM;  Seeley  JR;  Rohde  P:  A family study of major depressive disorder in a community sample of adolescents.  Arch Gen Psychiatry   2001; 58:13—20
[CrossRef] | [PubMed]
 
Sullivan  PF;  Neale  MC;  Kendler  KS:  Genetic epidemiology of major depression: review and meta-analysis.  Am J Psychiatry   2000; 157:1552—1562
[CrossRef] | [PubMed]
 
Downey  G;  Coyne  JC:  Children of depressed parents: an integrative review.  Psychol Bull   1990; 108:50—76
[CrossRef] | [PubMed]
 
Kovacs  M;  Devlin  B;  Pollock  M;  Richards  C;  Mukerji  P:  A controlled family history study of childhood-onset depressive disorder.  Arch Gen Psychiatry   1997; 54:613—623
[PubMed]
[CrossRef]
 
Lieb  R;  Isensee  B;  Hofler  M;  Pfister  H;  Wittchen  HU:  Parental major depression and the risk of depression and other mental disorders in offspring: a prospective-longitudinal community study.  Arch Gen Psychiatry   2002; 59:365—374
[CrossRef] | [PubMed]
 
Hammen  C;  Burge  D;  Burney  E;  Adrian  C:  Longitudinal study of diagnoses in children of women with unipolar and bipolar affective disorder.  Arch Gen Psychiatry   1990; 47:1112—1117
[PubMed]
[CrossRef]
 
Williamson  DE;  Birmaher  B;  Axelson  DA;  Ryan  ND;  Dahl  RE:  First episode of depression in children at low and high familial risk for depression.  J Am Acad Child Adolesc Psychiatry   2004; 43:291—297
[CrossRef] | [PubMed]
 
Brennan  PA;  Hammen  C;  Katz  AR;  Le Brocque  RM:  Maternal depression, paternal psychopathology, and adolescent diagnostic outcomes.  J Consult Clin Psychol   2002; 70:1075—1085
[CrossRef] | [PubMed]
 
Orvaschel  H;  Walsh-Allis  G;  Ye  WJ:  Psychopathology in children of parents with recurrent depression.  J Abnorm Child Psychol   1988; 16:17—28
[CrossRef] | [PubMed]
 
Kendler  KS;  Gardner  CO;  Prescott  CA:  Toward a comprehensive developmental model for major depression in women.  Am J Psychiatry   2002; 159:1133—1145
[CrossRef] | [PubMed]
 
Holmans  P;  Weissman  MM;  Zubenko  GS;  Scheftner  WA;  Crowe  RR;  Depaulo  JR  Jr;  Knowles  JA;  Zubenko  WN;  Murphy-Eberenz  K;  Marta  DH;  Boutelle  S;  McInnis  MG;  Adams  P;  Gladis  M;  Steele  J;  Miller  EB;  Potash  JB;  Mackinnon  DF;  Levinson  DF:  Genetics of recurrent early-onset major depression (GenRED): final genome scan report.  Am J Psychiatry   2007; 164:248—258
[CrossRef] | [PubMed]
 
Caspi  A;  Sugden  K;  Moffitt  TE;  Taylor  A;  Craig  IW;  Harrington  H;  McClay  J;  Mill  J;  Martin  J;  Braithwaite  A;  Poulton  R:  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.  Science   2003; 301:386—389
[CrossRef] | [PubMed]
 
Cicchetti  D;  Rogosch  FA;  Toth  SL:  Maternal depressive disorder and contextual risk: contributions to the development of attachment insecurity and behavior problems in toddlerhood.  Dev Psychopathol   1998; 10:283—300
[CrossRef] | [PubMed]
 
Weissman  MM;  Pilowsky  DJ;  Wickramaratne  PJ;  Talati  A;  Wisniewski  SR;  Fava  M;  Hughes  CW;  Garber  J;  Malloy  E;  King  CA;  Cerda  G;  Sood  AB;  Alpert  JE;  Trivedi  MH;  Rush  AJ; STAR*D-Child Team:  Remissions in maternal depression and child psychopathology: a STAR*D-Child report.  JAMA   2006; 295:1389—1398
[CrossRef] | [PubMed]
 
Fava  M;  Rush  AJ;  Trivedi  MH;  Nierenberg  AA;  Thase  ME;  Sackeim  HA;  Quitkin  FM;  Wisniewski  SR;  Lavori  PW;  Rosenbaum  JF;  Kupfer  DJ:  Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.  Psychiatr Clin North Am   2003; 26:457—494
[CrossRef] | [PubMed]
 
Rush  AJ;  Fava  M;  Wisniewski  SR;  Lavori  PW;  Trivedi  MH;  Sackeim  HA;  Thase  ME;  Nierenberg  AA;  Quitkin  FM;  Kashner  TM;  Kupfer  DJ;  Rosenbaum  JF;  Alpert  J;  Stewart  JW;  McGrath  PJ;  Biggs  MM;  Shores-Wilson  K;  Lebowitz  BD;  Ritz  L;  Niederehe  G; STAR*D Investigators Group:  Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design.  Control Clin Trials   2004; 25:119—142
[CrossRef] | [PubMed]
 
Beardslee  WR;  Gladstone  TR;  Wright  EJ;  Cooper  AB:  A family-based approach to the prevention of depressive symptoms in children at risk: evidence of parental and child change.  Pediatrics   2003; 112:e119—e131
[CrossRef] | [PubMed]
 
Verdeli  H;  Ferro  T;  Wickramaratne  P;  Greenwald  S;  Blanco  C;  Weissman  MM:  Treatment of depressed mothers of depressed children: pilot study of feasibility.  Depress Anxiety   2004; 19:51—58
[CrossRef] | [PubMed]
 
Garber  J;  Clarke  GN;  Weersing  VR;  Beardslee  WR;  Brent  DA;  Gladstone  TR;  DeBar  LL;  Lynch  FL;  D'Angelo  E;  Hollon  SD;  Shamseddeen  W;  Iyengar  S:  Prevention of depression in at-risk adolescents: a randomized controlled trial.  JAMA   2009; 301:2215—2224
[CrossRef] | [PubMed]
 
Swartz  HA;  Frank  E;  Zuckoff  A;  Cyranowski  JM;  Houck  PR;  Cheng  Y;  Fleming  MA;  Grote  NK;  Brent  DA;  Shear  MK:  Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment.  Am J Psychiatry   2008; 165:1155—1162
[CrossRef] | [PubMed]
 
Pilowsky  DJ;  Wickramaratne  PJ;  Rush  AJ;  Hughes  CW;  Garber  J;  Malloy  E;  King  CA;  Cerda  G;  Sood  AB;  Alpert  JE;  Wisniewski  SR;  Trivedi  MH;  Talati  A;  Carlson  MM;  Liu  HH;  Fava  M;  Weissman  MM:  Children of currently depressed mothers: a STAR*D ancillary study.  J Clin Psychiatry   2006; 67:126—136
[CrossRef] | [PubMed]
 
Pilowsky  DJ;  Wickramaratne  P;  Talati  A;  Tang  M;  Hughes  CW;  Garber  J;  Malloy  E;  King  C;  Cerda  G;  Sood  AB;  Alpert  JE;  Trivedi  MH;  Fava  M;  Rush  AJ;  Wisniewski  S;  Weissman  MM:  Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child study.  Am J Psychiatry   2008; 165:1136—1147
[CrossRef] | [PubMed]
 
Rush  AJ;  Trivedi  M;  Fava  M:  Depression, IV: STAR*D treatment trial for depression.  Am J Psychiatry   2003; 160:237
[CrossRef] | [PubMed]
 
Rush  AJ;  Warden  D;  Wisniewski  SR;  Fava  M;  Trivedi  MH;  Gaynes  BN;  Nierenberg  AA:  STAR*D: revising conventional wisdom.  CNS Drugs   2009; 23:627—647
[PubMed]
 
Endicott  J;  Cohen  J;  Nee  J;  Fleiss  J;  Sarantakos  S:  Hamilton Depression Rating Scale: extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia.  Arch Gen Psychiatry   1981; 38:98—103
[PubMed]
[CrossRef]
 
Hamilton  M:  A rating scale for depression.  J Neurol Neurosurg Psychiatry   1960; 23:56—62
[CrossRef] | [PubMed]
 
Rush  AJ;  Trivedi  MH;  Carmody  TJ;  Ibrahim  HM;  Markowitz  JC;  Keitner  GI;  Kornstein  SG;  Arnow  B;  Klein  DN;  Manber  R;  Dunner  DL;  Gelenberg  AJ;  Kocsis  JH;  Nemeroff  CB;  Fawcett  J;  Thase  ME;  Russell  JM;  Jody  DN;  Borian  FE;  Keller  MB:  Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.  Neuropsychopharmacology   2005; 30:405—416
[CrossRef] | [PubMed]
 
Rush  AJ;  Trivedi  MH;  Ibrahim  HM;  Carmody  TJ;  Arnow  B;  Klein  DN;  Markowitz  JC;  Ninan  PT;  Kornstein  S;  Manber  R;  Thase  ME;  Kocsis  JH;  Keller  MB:  The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.  Biol Psychiatry   2003; 54:573—583
[CrossRef] | [PubMed]
 
Trivedi  MH;  Rush  AJ;  Wisniewski  SR;  Nierenberg  AA;  Warden  D;  Ritz  L;  Norquist  G;  Howland  RH;  Lebowitz  B;  McGrath  PJ;  Shores-Wilson  K;  Biggs  MM;  Balasubramani  GK;  Fava  MSTAR*D Study Team:  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.  Am J Psychiatry   2006; 163:28—40
[CrossRef] | [PubMed]
 
Kaufman  J;  Martin  A;  King  RA;  Charney  D:  Are child-, adolescent-, and adult-onset depression one and the same disorder? Biol Psychiatry   2001; 49:980—1001
[CrossRef] | [PubMed]
 
Weissman  MM;  Warner  V;  Wickramaratne  P;  Moreau  D;  Olfson  M:  Offspring of depressed parents: 10 years later.  Arch Gen Psychiatry   1997; 54:932—940
[PubMed]
[CrossRef]
 
Achenbach  TM;  Howell  CT;  Quay  HC;  Conners  CK:  National survey of problems and competencies among four- to sixteen-year-olds: parents' reports for normative and clinical samples.  Monogr Soc Res Child Dev   1991; 56:1—131
[CrossRef] | [PubMed]
 
Shaffer  D;  Gould  MS;  Brasic  J;  Ambrosini  P;  Fisher  P;  Bird  H;  Aluwahlia  S:  A Children's Global Assessment Scale (CGAS).  Arch Gen Psychiatry   1983; 40:1228—1231
[PubMed]
[CrossRef]
 
Liang  KY;  Zeger  SL:  Longitudinal data analysis using generalized linear models.  Biometrika   1986; 73:13—22
[CrossRef]
 
Galecki  AT:  General class of covariance structures for two or more repeated factors in longitudinal data analysis.  Communications in Statistics   1994; 23:3105—3120
[CrossRef]
 
Rush  AJ;  Trivedi  MH;  Wisniewski  SR;  Nierenberg  AA;  Stewart  JW;  Warden  D;  Niederehe  G;  Thase  ME;  Lavori  PW;  Lebowitz  BD;  McGrath  PJ;  Rosenbaum  JF;  Sackeim  HA;  Kupfer  DJ;  Luther  J;  Fava  M:  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.  Am J Psychiatry   2006; 163:1905—1917
[CrossRef] | [PubMed]
 
Gunlicks  ML;  Weissman  MM:  Change in child psychopathology with improvement in parental depression: a systematic review.  J Am Acad Child Adolesc Psychiatry   2008; 47:379—389
[CrossRef] | [PubMed]
 
Brent  DA;  Kolko  DJ;  Birmaher  B;  Baugher  M;  Bridge  J;  Roth  C;  Holder  D:  Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression.  J Am Acad Child Adolesc Psychiatry   1998; 37:906—914
[CrossRef] | [PubMed]
 
Weissman  MM;  Olfson  M:  Translating intergenerational research on depression into clinical practice.  JAMA   2009; 302:2695—2696
[CrossRef] | [PubMed]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles
Perinatal mental health.
The Journal of nervous and mental disease 2011 Aug